Laurence Thomas
Optometrist · Dallas, TXNPI 1316901291
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $100,221 of the $103,026 with a category attached, or 97.3%. Konan Medical USA, Inc. accounts for 93.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2020 at $49,104 and has fallen 99.8% since, to $83 in 2025. Among optometrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $1493.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Konan Medical USA, Inc.$96K
- Johnson & Johnson Vision Care, Inc.$5K
- Optovue, Inc.$1K
- Bausch & Lomb Americas Inc.$351
- AbbVie$181
- Lombart Brothers, Inc.$161
- plus $681 from 13 others
What the payments were for
- Consulting fees$100,22197%
- Speaking & faculty fees$1,0001%
- Food & beverage$1,6432%
- Gifts$1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Konan Medical USA, Inc. | 10 | $96,000 |
| Johnson & Johnson Vision Care, Inc. | 16 | $4,565 |
| Optovue, Inc. | 2 | $1,087 |
| Bausch & Lomb Americas Inc. | 8 | $351 |
| AbbVie(2 entities) | 9 | $181 |
| Lombart Brothers, Inc. | 1 | $161 |
| Alcon | 5 | $143 |
| Visionix USA, Inc | 2 | $123 |
| Tarsus Pharmaceuticals, Inc. | 4 | $114 |
| Rxsight Inc | 1 | $84 |
| Sun Pharmaceutical Industries Inc. | 2 | $56 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $38 |
| Dompe US, Inc. | 1 | $24 |
| Novartis | 1 | $20 |
| Sight Sciences, Inc. | 1 | $19 |
| Reichert, Inc. | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Coopervision Inc. | 1 | $16 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,026 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SimbrinzaBrinzolamide/Brimonidine Tart | 138 | $30,677 |
| CombiganBrimonidine Tartrate/Timolol | 76 | $29,592 |
| LumiganBimatoprost | 67 | $29,170 |
| VyzultaLatanoprostene Bunod | 38 | $18,081 |
| MieboPerfluorohexyloctane/Pf | 21 | $15,878 |
| Alphagan PBrimonidine Tartrate | 38 | $15,571 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $12,430 |
| Brimonidine Tartrate | 32 | $9,275 |
| Brinzolamide | 48 | $7,867 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 58 | $7,468 |
| Travoprost | 31 | $4,244 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 158 | $3,016 |
| Timolol MaleateTimolol Maleate/Pf | 13 | $1,406 |
| Prednisolone Acetate | 42 | $1,396 |
| Latanoprost | 179 | $1,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan, Alphagan P | $181 | $74,332181 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $351 | $33,95959 claims |
| AlconSimbrinza | $143 | $30,677138 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $17 | $12,43016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Dallas
- Kenneth UzickDallas$61K
- Lilia FloresDallas$22K
- Derek CunninghamAustin$940K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Luis RojasMcKinney$309K
- Emile FadelAustin$225K
- Bridgitte LeeHouston$222K
- Phillip BrunsonHouston$214K
- Jill AutryBellaire$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.